Osamu Yokosuka is an Emeritus Professor of Chiba University, Japan. He graduated from Chiba University School of Medicine in 1975 then worked as a trainee under Professor K. Okuda in Chiba University Hospital till 1978. Dr. Yokosuka was a research fellow worked under Professor S. Scherlock and Professor B. H. Billing in Royal Free Hospital, London, UK from 1978 to 1980; under Professor M. Omata in Chiba University from 1980 to 1985; and under Dr. J Summers in Fox Chase Cancer Center, PA, USA in 1984. In 1985, he received a Degree of Doctor of Medical Science, and served as an Assistant Professor in Chiba University till 1994, then as Lecturer in Medicine till 2006 when he was appointed as Director and Professor of Medicine. From 2013 to 2015, he served as the Dean of Chiba University School of Medicine.
Dr. Yokosuka was the Secretary General of APASL (2008-2014). In 2016, he was elected as the President of APASL Tokyo, the President of 52nd Annual Meeting of Japan Society of Hepatology, and the President of Funabashi Central Hospital. Dr. Yokosuka’s research mainly focuses on Hepatitis and Hepatocellular Carcinoma. So far, he has published more than 700 original papers.
Tatsuo Kanda received a medical degree in 1991 at Niigata University School of Medicine, Japan, and his PhD in 1999 at Chiba University Graduate School of Medicine, Japan. He had post-doctor training for 3 years under Prof. Ratna Ray and Prof. Ranjit Ray at Saint Louis University, St. Louis, MO, USA. In Dec. 2008, Tatsuo Kanda became a Tenure-track Associate Professor at Department of Medicine and Clinical Oncology, Chiba University, Graduate School of Medicine, Japan. In Feb. 2013, Tatsuo Kanda was nominated a permanent Associate Professor at Department of Gastroenterology and Nephrology, Chiba University, Graduate School of Medicine, Japan. In 2017, Tatsuo Kanda became an Associate Professor, Division of Gastroenterology and Hepatology, Department of Internal Medicine, Nihon University School of Medicine. For ~25 years, he has focused his scientific interests on the topics related to liver diseases including acute liver failure, viral hepatitis and autoimmune liver diseases, and worked with Prof. Osamu Yokosuka. Tatsuo Kanda is also an expert for hepatitis A virus (HAV), HBV and HCV, and translation and replication of these viruses, and hepatocarcinogenesis. With his expertise in antiviral therapies and hepatitis virus research, Tatsuo Kanda also sees a lot of patients in clinical daily practice. Tatsuo Kanda has published more than 200 articles in peer-reviewed Journal.
Herbal Medicines for the Treatment of Metabolic Syndrome
Srinivas Nammi, PhD
About This Topic
Metabolic syndrome is posed as a significant health burden around the world and is a major high‐risk factor of type 2 diabetes. It is described as a pre-diabetic condition that includes obesity, dyslipidemia, impaired fasting glucose and/or impaired glucose tolerance, and reduced insulin sensitivity. The development of metabolic syndrome is influenced by a combination of genetic and environmental factors. The modern lifestyle of increased intake of high-calorie cafeteria fast food associated with decreased energy expenditure is among the environmental factors that contribute to the pandemic of metabolic syndrome. To reduce the constellation of events of hyperglycemia and hyperlipidemia, a multi-targeted approach controlling both glucose and lipid metabolism is needed. The currently available therapeutic options such as exercise, dietary modification, or a combination of synthetic anti‐diabetic, and anti-hyperlipidemic drugs possess their own limitations and a multitude of undesirable side effects. Hence, there is an increased demand to search and evaluate traditional approaches for the treatment of metabolic disorders, particularly the use of herbal medicines. Recently, there has been a resurgence of interest in the use of herbal medicines because of their reduced side effects compared to synthetic drugs. Thus, herbal medicines may represent future hope for the pharmacological management of metabolic syndrome firstly, as an important source of new lead molecules for the development of future single molecule-based synthetic drugs, and secondly as single- or multi-herbal formulae due to their multi-component, multi-targeted actions.
This special issue is dedicated to integrate the pharmacological actions and mechanisms of herbal preparations, extracts, isolated compounds, and semi-synthetic derivatives in the prevention and treatment of metabolic syndrome. We cordially invite researchers to contribute their original research articles and reviews on preclinical and clinical evaluation of herbal medicines in our special issue titled "Herbal Medicines for the Treatment of Metabolic Syndrome”
Potential topics include, but are not limited to:
Title: Phytohormones active against inflammation-driven metabolic syndrome symptoms and co-morbidities
Title：The effects of St.John’s wort on metabolic syndrome
Title: Anti obesity and anti diabetic properties of Angekica keiskei (Ashitaba)
Title: The effects of Herbal medicines used with Jamaican women and their infants during pregnancy, postpartum and infancy
Title: Protective effects of flavonoids in herbs on cardiovascular diseases